What Is P21?
P21 (also written P021) is a small synthetic peptide derived from the biologically active region of ciliary neurotrophic factor (CNTF), engineered to promote neurogenesis and neuroprotection. It was developed in Khalid Iqbal’s laboratory at the New York State Institute for Basic Research; the peptide carries an adamantylated modification to improve blood–brain-barrier penetration and resist breakdown. In research it is studied as a candidate treatment for cognitive decline, Alzheimer’s disease, and other neurodegenerative conditions. It is a research compound, not an approved medicine or dietary supplement, and there are no published human clinical trials.
Evidence
The evidence for P21 is entirely preclinical (rodent). Chronic administration in aged rats reduced age-dependent decline in learning and memory and was associated with markers of restored hippocampal function, supporting the idea that stimulating endogenous neurogenic/neurotrophic pathways could counter cognitive aging 1Reference 1AnimalRescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound — rat studyView study →. In transgenic Alzheimer’s-model mice, treatment with the peptide prevented dendritic and synaptic deficits and cognitive impairment 2Reference 2AnimalPrevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound — mouse studyView study →. These are consistent and encouraging animal findings, but they are animal findings: no human trial of P21 exists in this pass, so its efficacy and safety in people are unproven, and popular claims that it “boosts neurogenesis” in humans are not backed by a verified clinical study.
Dosage & Safety
There is no established human dose for P21 and no controlled human safety data; any regimens circulating online are extrapolated from animal work, and this page makes no dosing recommendation. P21 is not FDA-approved and is not an approved dietary supplement. Human safety, drug interactions, long-term effects, and pregnancy/lactation safety are not established and have not been assessed in this pass. This entry is informational only and is not an endorsement of use.
References
- Bolognin S, Buffelli M, Puoliväli J, Iqbal K. (2014). Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound — rat study. Neurobiol Aging. https://pubmed.ncbi.nlm.nih.gov/24702821/
- Kazim SF, Blanchard J, Bianchi R, Iqbal K. (2017). Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound — mouse study. Alzheimers Res Ther. https://pubmed.ncbi.nlm.nih.gov/28655344/